Results 91 to 100 of about 1,494 (190)

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

, 2016
International audienceBlastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is an aggressive hematological malignancy with a poor prognosis that derives from PDCs.
Fanny Angelot-Delettre, Claude Preudhomme, Macintyre, Elisabeth, Baptiste Lamarthée, Francis Bonnefoy, Lagrost, Laurent, David Masson, Bonnefoy, Francis, Roggy, Anne, Philippe, Laure, Angelot-Delettre, Fanny, Saas, Philippe, Cécile Chagué, Christophe Roumier, Biichle, Sabeha, Perruche, Sylvain, Sylvain Perruche, Roumier, Christophe, Laure Philippe, Chague, Cecile, Garnache-Ottou, Francine, Adam Ceroi, Elisabeth Macintyre, Francine Garnache-Ottou, Lamarthee, Baptiste, Philippe Saas, Masson, David, Thierry Gauthier, Laurent Lagrost, Preudhomme, Claude, Anne Roggy, Ceroi, Adam, Sabeha Biichle, Gauthier, Thierry   +33 more
core   +1 more source

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

, 2016
International audienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and largely incurable hematologic malignancy originating from plasmacytoid dendritic cells (pDCs).
Wright, George, Shaffer, Arthur L, Chaperot, Laurence, Kelly, Priscilla N, Hou, Zhiying Esther, Pittaluga, Stefania, Marcucci, Guido, Evbuomwan, Moses O, Forman, Stephen J, Xiao, Wenming, Plumas, Joel, Thomas, Craig J, Ferrer, Marc, Ganapathi, Karthik, Guha, Rajarshi, Staudt, Louis M, Huang, da Wei, Jaffe, Elaine S, Ceribelli, Michele, Zhang, Xiaohu, Reizis, Boris   +20 more
core   +1 more source

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy with poor outcomes. Existing data on the clinical behavior of BPDCN are limited because reported outcomes are from small retrospective series, and standardized ...
Stevenson, Kristen E, Stone, Richard M, Brunner, Andrew M, Rampal, Raajit K, Lane, Andrew A, Louissaint, Jr, Abner, Haddadin, Michael, Dogan, Ahmet, Neuberg, Donna S, Upadhyay, Vivek A, Horwitz, Steven M, Tallman, Martin S, Fathi, Amir T, Mehta-Shah, Neha, Lovitch, Scott B, Taylor, Justin, Grussie, Erwin   +16 more
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Blood and Lymphatic Cancer: Targets and Therapy, 2017
Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+
Trottier AM, Cerquozzi S, Owen CJ
doaj  

Bruise-like cutaneous lesions as the early presentation of blastic plasmacytoid dendritic cell neoplasm

Dermatologica Sinica, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and highly aggressive hematopoietic malignancy associated with a poor prognosis. It has been recognized to originate from precursors of plasmacytoid dendritic cells and has recently been
Yi-Hsuan Chou, Ruey-Yi Lin, Meng-Sui Lee, Hsiao-Ping Wu, Che-Pin Lin, Chen-Yi Wu   +5 more
doaj   +1 more source

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, male-biased (>3:1 M:F) hematologic malignancy in which some patients have bone marrow involvement at diagnosis (50%) and most have tumor formation in the skin (~90%), often preceding ...
Togami, Katsuhiro, Seiler, Michael, Biichle, Sabeha, Madan, Vikas, Angelot-Delletre, Fanny, Konopleva, Marina, Lane, Andrew A, Chung, Sun Sook, Louissaint, Abner, Griffin, Gabriel K, Ghandi, Mahmoud, Li, Jia, Koeffler, H. Phillip, Piccaluga, Pier Paolo, Kenyon, Christopher M., Yang, Henry, Abdel-Wahab, Omar, Lovitch, Scott B, Taylor, Justin, Kim, Sunhee, Weinstock, David M., Li, Yvonne Y., Garnache-Ottou, Francine, Morgan, Elizabeth A, Cabal-Hierro, Lucia, Pemmaraju, Naveen, Buonamici, Silvia, Hammerman, Peter S., Jardin, Fabrice, Justin Taylor, Naveen Pemmaraju, David M. Weinstock, H. Phillip Koeffler, Andrew A Lane, Silvia Buonamici, Jia Li, Omar Abdel-Wahab, Fabrice Jardin, Katsuhiro Togami, Pier Paolo Piccaluga, Christopher M. Kenyon, Francine Garnache-Ottou, Michael Seiler, Sunhee Kim, Vikas Madan, Lucia Cabal-Hierro, Scott B Lovitch, Yvonne Y. Li, Gabriel K Griffin, Mahmoud Ghandi, Henry Yang, Abner Louissaint, Peter S. Hammerman, Elizabeth A Morgan, Sabeha Biichle, Fanny Angelot-Delletre, Sun Sook Chung, Marina Konopleva   +57 more
core   +1 more source

A Multidisciplinary Approach to Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Practical Recommendations and Insights from Countries of the Gulf Cooperation Council

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematopoietic malignancy characterized by cutaneous and systemic hematologic involvement.
Ayman Al Hejazi, Phyu P. Aung, Nasir Bakshi, Robert S. Ohgami, Haitham Khogeer, Hatim Al-Maghraby, Ahmad S. Alotaibi, Rania Medhat Seliem, Heba Raslan, Areej Al Mugairi, Ramesh Pandita   +10 more
core   +1 more source

Supplementary Figure 5 from Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

, 2017
Time and dose-dependent response of primary BPDCN to venetoclax in vitro. (A) Cell death measurement by flow cytometry at 4 and 8 hours after addition of venetoclax at the indicated doses in a primary BPDCN, represented as change in Annexin V positivity ...
Joan Montero (11411789), Lucia Cabal-Hierro (15077340), Leah J. Hogdal (15101898), Marina Konopleva (31485), Richard M. Stone (2555110), Katsuhiro Togami (15102618), Jon C. Aster (7449173), Naveen Pemmaraju (824394), Anthony Letai (1335960), Andrew A. Lane (12220577), Elizabeth A. Morgan (14922168), Ilene Galinsky (64265), Jason Stephansky (15102615), Tianyu Cai (11805018), Matthew S. Davids (8564955), Nicole R. LeBoeuf (10344512), Gabriel K. Griffin (12220574)   +16 more
core   +1 more source

CD103 Expression on Blastic Plasmacytoid Dendritic Cell Neoplasms in Peripheral Blood and Bone Marrow Samples

, 2020
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive neoplasm which is typically CD4+, CD56+, and CD123+. There is limited information regarding CD103 expression on blastic plasmacytoid dendritic cell neoplasms.
Thomason Ron, Ullery Sally, Ron Lee, Sally Ullery, Ron Thomason, Lee Ron   +5 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function

, 2016
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy thought to result from transformation of plasmacytoid dendritic cells (pDCs). Clinical outcomes are poor and pathogenesis is unclear. To better understand BPDCN genomics and
Togami, Katsuhiro, Seiler, Michael, Biichle, Sabeha, Sarkizova, Siranush, Garnache-Ottou, Francine, Lane, Andrew A., Madan, Vikas, Angelot-Delettre, Fanny, Ghandi, Mahmoud, Hammerman, Peter S, Li, Jia, Li, Yvonne, Koeffler, H. Phillip, Villani, Alexandra-Chloe, Buonamici, Silvia, Yang, Henry, Abdel-Wahab, Omar, Buczkowski, Kevin, Hacohen, Nir, Taylor, Justin   +19 more
core   +1 more source